Literature DB >> 17159614

Vasectomy in men with primary progressive aphasia.

Sandra Weintraub1, Christopher Fahey, Nancy Johnson, Marek-Marsel Mesulam, Darren R Gitelman, Bing B Weitner, Alfred Rademaker.   

Abstract

OBJECTIVE: To study the frequency of vasectomy in men with primary progressive aphasia (PPA).
BACKGROUND: PPA is a dementia syndrome in which aphasia emerges in relative isolation during the initial stages of illness. On the basis of a clinical observation in a patient who dated the onset of symptoms to the period after a vasectomy, and because of the curious sharing of the tau protein exclusively by brain and sperm, vasectomy rates were examined in men with PPA.
METHOD: This study used a case control design. Forty-seven men with PPA and 57 men with no cognitive impairment (NC) between 55 and 80 years of age were surveyed about a history of vasectomy.
RESULTS: The age-adjusted rate of vasectomy in PPA patients (40%) was higher than in NC (16%, P=0.02). There was a younger age at onset for the patients with vasectomy (58.8 vs. 62.9 y, P=0.03).
CONCLUSIONS: Vasectomy may constitute one risk factor for PPA in men. Potential mechanisms mediating risk include vasectomy-induced immune responses to sperm, which shares antigenic epitopes with brain. Antisperm antibodies can also develop in women and become risk factors for PPA.

Entities:  

Mesh:

Year:  2006        PMID: 17159614     DOI: 10.1097/01.wnn.0000213923.48632.ab

Source DB:  PubMed          Journal:  Cogn Behav Neurol        ISSN: 1543-3633            Impact factor:   1.600


  11 in total

Review 1.  An update on primary progressive aphasia.

Authors:  Emily Rogalski; Marsel Mesulam
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

2.  A critical analysis of the reported association between vasectomy and frontotemporal dementia.

Authors:  Tobias S Köhler; Jeremy T Choy; Anees A Fazili; Joel F Koenig; Robert E Brannigan
Journal:  Asian J Androl       Date:  2012-10-15       Impact factor: 3.285

3.  TDP-43 frontotemporal lobar degeneration and autoimmune disease.

Authors:  Zachary A Miller; Katherine P Rankin; Neill R Graff-Radford; Leonel T Takada; Virginia E Sturm; Clare M Cleveland; Lindsey A Criswell; Philipp A Jaeger; Trisha Stan; Kristin A Heggeli; Sandy Chan Hsu; Anna Karydas; Baber K Khan; Lea T Grinberg; Maria Luisa Gorno-Tempini; Adam L Boxer; Howard J Rosen; Joel H Kramer; Giovanni Coppola; Daniel H Geschwind; Rosa Rademakers; William W Seeley; Tony Wyss-Coray; Bruce L Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-03-30       Impact factor: 10.154

Review 4.  Are there susceptibility factors for primary progressive aphasia?

Authors:  Emily Rogalski; Sandra Weintraub; M-Marsel Mesulam
Journal:  Brain Lang       Date:  2013-03-13       Impact factor: 2.381

Review 5.  Primary progressive aphasia and the evolving neurology of the language network.

Authors:  M-Marsel Mesulam; Emily J Rogalski; Christina Wieneke; Robert S Hurley; Changiz Geula; Eileen H Bigio; Cynthia K Thompson; Sandra Weintraub
Journal:  Nat Rev Neurol       Date:  2014-09-02       Impact factor: 42.937

Review 6.  Clinical trajectories and biological features of primary progressive aphasia (PPA).

Authors:  E J Rogalski; M M Mesulam
Journal:  Curr Alzheimer Res       Date:  2009-08       Impact factor: 3.498

7.  Progress in the last decade in our understanding of primary progressive aphasia.

Authors:  Ellajosyula Ratnavalli
Journal:  Ann Indian Acad Neurol       Date:  2010-12       Impact factor: 1.383

Review 8.  Primary progressive aphasias and their contribution to the contemporary knowledge about the brain-language relationship.

Authors:  Michał Harciarek; Andrew Kertesz
Journal:  Neuropsychol Rev       Date:  2011-08-02       Impact factor: 7.444

Review 9.  Vasectomy and prostate cancer risk: a historical synopsis of undulating false causality.

Authors:  Max Nutt; Zachary Reed; Tobias S Köhler
Journal:  Res Rep Urol       Date:  2016-07-18

10.  A review on primary progressive aphasia.

Authors:  Gabriel C Léger; Nancy Johnson
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.